These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15320784)

  • 1. Salutary properties of YC-1 in the cardiovascular and hematological systems.
    Tulis DA
    Curr Med Chem Cardiovasc Hematol Agents; 2004 Oct; 2(4):343-59. PubMed ID: 15320784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YC-1 stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells.
    Liu XM; Peyton KJ; Mendelev NN; Wang H; Tulis DA; Durante W
    Mol Pharmacol; 2009 Jan; 75(1):208-17. PubMed ID: 18923065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.
    Schmidt K; Schrammel A; Koesling D; Mayer B
    Mol Pharmacol; 2001 Feb; 59(2):220-4. PubMed ID: 11160856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.
    Friebe A; Müllershausen F; Smolenski A; Walter U; Schultz G; Koesling D
    Mol Pharmacol; 1998 Dec; 54(6):962-7. PubMed ID: 9855623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
    Turgut NH; Temiz TK; Turgut B; Karadas B; Parlak M; Bagcivan I
    Can J Physiol Pharmacol; 2013 Oct; 91(10):797-803. PubMed ID: 24144050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.
    Wohlfart P; Malinski T; Ruetten H; Schindler U; Linz W; Schoenafinger K; Strobel H; Wiemer G
    Br J Pharmacol; 1999 Nov; 128(6):1316-22. PubMed ID: 10578147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapies for cyclic GMP control of vascular smooth muscle growth.
    Tulis DA
    Am J Ther; 2008; 15(6):551-64. PubMed ID: 19127140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
    Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
    Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon monoxide relaxes the female pig urethra as effectively as nitric oxide in the presence of YC-1.
    Schroder A; Hedlund P; Andersson KE
    J Urol; 2002 Apr; 167(4):1892-6. PubMed ID: 11912455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
    Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
    Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
    Dismuke WM; Sharif NA; Ellis DZ
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
    Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
    Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation.
    Tulis DA; Durante W; Peyton KJ; Chapman GB; Evans AJ; Schafer AI
    Biochem Biophys Res Commun; 2000 Dec; 279(2):646-52. PubMed ID: 11118339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.
    Martin E; Lee YC; Murad F
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):12938-42. PubMed ID: 11687640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
    Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
    Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function.
    Tulis DA; Bohl Masters KS; Lipke EA; Schiesser RL; Evans AJ; Peyton KJ; Durante W; West JL; Schafer AI
    Biochem Biophys Res Commun; 2002 Mar; 291(4):1014-21. PubMed ID: 11866467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evolutionarily conserved mechanism for sensitization of soluble guanylyl cyclase reveals extensive nitric oxide-mediated upregulation of cyclic GMP in insect brain.
    Ott SR; Delago A; Elphick MR
    Eur J Neurosci; 2004 Sep; 20(5):1231-44. PubMed ID: 15341595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide.
    Hoenicka M; Becker EM; Apeler H; Sirichoke T; Schröder H; Gerzer R; Stasch JP
    J Mol Med (Berl); 1999 Jan; 77(1):14-23. PubMed ID: 9930922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats.
    Hsieh GC; O'Neill AB; Moreland RB; Sullivan JP; Brioni JD
    Eur J Pharmacol; 2003 Jan; 458(1-2):183-9. PubMed ID: 12498924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition.
    Garthwaite G; Goodwin DA; Neale S; Riddall D; Garthwaite J
    Mol Pharmacol; 2002 Jan; 61(1):97-104. PubMed ID: 11752210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.